158 related articles for article (PubMed ID: 38016912)
1. Triple Negative Breast Cancers: An Obsolete Entity?
Keskinkılıc M; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2024 Jan; 24(1):1-6. PubMed ID: 38016912
[TBL] [Abstract][Full Text] [Related]
2. An overview of triple negative breast cancer for surgical oncologists.
Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
[TBL] [Abstract][Full Text] [Related]
3. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
6. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
[TBL] [Abstract][Full Text] [Related]
7. De-escalating systemic therapy in triple negative breast cancer: The example of secretory carcinoma.
Benabu JC; Stoll F; Koch A; Molière S; Bellocq JP; Mathelin C
J Gynecol Obstet Hum Reprod; 2018 Apr; 47(4):163-165. PubMed ID: 29409947
[TBL] [Abstract][Full Text] [Related]
8. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review.
Lu B; Natarajan E; Balaji Raghavendran HR; Markandan UD
Technol Cancer Res Treat; 2023; 22():15330338221145246. PubMed ID: 36601658
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
Lee YM; Oh MH; Go JH; Han K; Choi SY
Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.
El Hachem G; Gombos A; Awada A
F1000Res; 2019; 8():. PubMed ID: 31069063
[TBL] [Abstract][Full Text] [Related]
12. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
13. LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer.
Lv M; Xu P; Wu Y; Huang L; Li W; Lv S; Wu X; Zeng X; Shen R; Jia X; Yin Y; Gu Y; Yuan H; Xie H; Fu Z
Oncotarget; 2016 Mar; 7(11):13047-59. PubMed ID: 26910840
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
15. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.
Newman LA; Reis-Filho JS; Morrow M; Carey LA; King TA
Ann Surg Oncol; 2015 Mar; 22(3):874-82. PubMed ID: 25527230
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
17. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
Elfgen C; Varga Z; Reeve K; Moskovszky L; Bjelic-Radisic V; Tausch C; Güth U
Breast Cancer Res Treat; 2019 Aug; 177(1):67-75. PubMed ID: 31154578
[TBL] [Abstract][Full Text] [Related]
18. Triple negative breast cancer: the kiss of death.
Jitariu AA; Cîmpean AM; Ribatti D; Raica M
Oncotarget; 2017 Jul; 8(28):46652-46662. PubMed ID: 28445140
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Triple-Negative Breast Cancer.
Derakhshan F; Reis-Filho JS
Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
[TBL] [Abstract][Full Text] [Related]
20. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
